Lyra Therapeutics, Inc. (LYRA)
NASDAQ: LYRA · Real-Time Price · USD
0.191
+0.013 (7.13%)
Nov 21, 2024, 12:30 PM EST - Market open
Lyra Therapeutics Revenue
Lyra Therapeutics had revenue of $195.00K in the quarter ending September 30, 2024, a decrease of -64.15%. This brings the company's revenue in the last twelve months to $1.47M, up 3.37% year-over-year. In the year 2023, Lyra Therapeutics had annual revenue of $1.56M with 14.31% growth.
Revenue (ttm)
$1.47M
Revenue Growth
+3.37%
P/S Ratio
7.76
Revenue / Employee
$16,716
Employees
88
Market Cap
12.49M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
China Jo-Jo Drugstores | 154.54M |
Trinity Biotech | 59.13M |
ImmunoPrecise Antibodies | 17.44M |
Aspira Women's Health | 8.96M |
QT Imaging Holdings | 4.04M |
PAVmed | 4.03M |
Immuron | 3.27M |
Talphera | 281.00K |
LYRA News
- 8 days ago - Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 weeks ago - Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis - GlobeNewsWire
- 7 weeks ago - Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings - GlobeNewsWire
- 3 months ago - Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital - GlobeNewsWire
- 7 months ago - Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis - GlobeNewsWire
- 7 months ago - Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 months ago - 3 'Buy-Rated' Biotech Stocks Under $10 - Seeking Alpha